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The long-term benefit-to-risk ratio of sustained antipsychotic treatment for schizophrenia has recently been questioned. In this paper, we critically
examine the literature on the long-term efficacy and effectiveness of this treatment. We also review the evidence on the undesired effects, the impact
on physical morbidity and mortality, as well as the neurobiological correlates of chronic exposure to antipsychotics. Finally, we summarize factors
that affect the risk-benefit ratio. There is consistent evidence supporting the efficacy of antipsychotics in the short term and mid term following sta-
bilization of acute psychotic symptoms. There is insufficient evidence supporting the notion that this effect changes in the long term. Most, but not
all, of the long-term cohort studies find a decrease in efficacy during chronic treatment with antipsychotics. However, these results are inconclusive,
given the extensive risk of bias, including increasing non-adherence. On the other hand, long-term studies based on national registries, which
have lower risk of bias, find an advantage in terms of effectiveness during sustained antipsychotic treatment. Sustained antipsychotic treatment
has been also consistently associated with lower mortality in people with schizophrenia compared to no antipsychotic treatment. Nevertheless,
chronic antipsychotic use is associated with metabolic disturbance and tardive dyskinesia. The latter is the clearest undesired clinical consequence
of brain functioning as a potential result of chronic antipsychotic exposure, likely from dopaminergic hypersensitivity, without otherwise clear evi-
dence of other irreversible neurobiological changes. Adjunctive psychosocial interventions seem critical for achieving recovery. However, overall, the
current literature does not support the safe reduction of antipsychotic dosages by 50% or more in stabilized individuals receiving adjunctive psy-
chosocial interventions. In conclusion, the critical appraisal of the literature indicates that, although chronic antipsychotic use can be associated
with undesirable neurologic and metabolic side effects, the evidence supporting its long-term efficacy and effectiveness, including impact on life
expectancy, outweighs the evidence against this practice, overall indicating a favorable benefit-to-risk ratio. However, the finding that a minority
of individuals diagnosed initially with schizophrenia appear to be relapse free for long periods, despite absence of sustained antipsychotic treat-
ment, calls for further research on patient-level predictors of positive outcomes in people with an initial psychotic presentation.
Key words: Long-term antipsychotic treatment, schizophrenia, benefit-to-risk ratio, efficacy, effectiveness, physical morbidity, mortality,
metabolic disturbance, tardive dyskinesia, psychosocial interventions, non-adherence, dopaminergic hypersensitivity
(World Psychiatry 2018;17:149–160)
Schizophrenia is a disorder character-
ized by acute episodes often followed by
symptom improvement1. Most guidelines
recommend at least 1-2 years of antipsy-
chotic treatment after symptom remis-
sion of an acute episode2-5. Of those dis-
continuing antipsychotic treatment, up
to 75% have a relapse within 12 to 18
months6,7. Meta-analyses of 26 to 52
week studies comparing second-genera-
tion antipsychotics vs. placebo in the
prevention of relapse found a very fa-
vorable number-needed-to-treat (NNT)
of 3-58,9.
Risks of acute antipsychotic treatment,
compared with placebo, mostly include
weight gain, metabolic disturbance, QTc
prolongation, neurologic adverse effects
and sedation10. It is generally accepted
that, given the usually moderate magni-
tude of these potential side effects and
the availability of strategies to manage
them, as well as the efficacy of antipsy-
chotics in preventing relapse, antipsycho-
tics have a favorable risk-benefit balance
during the first 1-2 years following an
acute psychotic episode2-5,11.
Clinical guidelines do not provide sys-
tematic recommendations for treatment
continuation or discontinuation beyond
1-2 years, yet they warn about the risks
of relapse associated with treatment dis-
continuation2-5,11. The effects of antipsy-
chotic treatment beyond the first 2 years
of treatment are not well understood,
given the lack of double-blind, placebo-
controlled randomized trials (RCTs)9.
There has been an emerging body of
literature on the long-term effects of anti-
psychotics questioning their necessity12-15.
Long-term animal studies of antipsycho-
tic exposure16, naturalistic cohorts14,15,
and treatment discontinuation studies13
have been cited by some authors who
claim that antipsychotics do not improve
outcomes in the long term, and that there
may even be iatrogenic adverse conse-
quences of long-term antipsychotic treat-
ment17. Others suggest that there is in-
sufficient evidence supporting iatrogenic
effects18. Such debate, and the uncer-
tainty in the interpretation of long-term
studies, with inherent biases12,19, results in
unclear recommendations for clinicians.
In this paper, we review the literature
on the potential risks and benefits of long-
term antipsychotic treatment, summa-
rizing the evidence of efficacy, effective-
ness, tolerability, physical morbidity and
mortality, as well as functional and struc-
tural brain changes associated with that
treatment. Additionally, we review the role
of interventions to optimize such risk-
benefit ratio.
EFFICACY, EFFECTIVENESS AND
TOLERABILITY
The longer the study, the more likely
that systematic error accumulates over
time and biases the results. Measurements
tend to prioritize feasibility over reliability;
the intervention is less controlled due to
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greater influence of environmental fac-
tors; and there is greater chance of sys-
tematic or non-random drop-outs differ-
ing between the arms of the trial.
Hence, the interpretation of the re-
sults should consider how each one of
these potential biases affects the study.
Interpretation should also consider the
literature, not isolated studies. Here, we
summarize the available data separately
for different methodological approaches,
as all have their own strengths and limi-
tations20-22.
Treatment adherence and long-
acting injectable antipsychotic
studies
The longer the treatment, the greater
the chance of insufficient adherence9,23,24.
Data from administrative claims in the
US suggest that, in clinical practice, pa-
tients with psychosis treated in an out-
patient setting fill their prescriptions an
average of 40-60% of the days prescrib-
ed25. Adherence studies find that poor
mid-term adherence ranges from 11.6%
based on self-report to 58.4% in studies
using serum concentration23. In addition
to high rates of insufficient adherence24,
we lack practical/reliable measures of
exposure26.
In a systematic review and meta-
analysis of longitudinal studies examin-
ing relapse and its risk factors in patients
following stabilization after a first psy-
chotic episode, non-adherence was found
to be the greatest predictor of relapse
among twenty variables in seven long-
term studies, increasing the chance of re-
lapse by 400%27. Individuals in another
study with non-adherence for >1 month
of an 18-month follow-up had a five-
fold greater chance of relapse than indi-
viduals with continuous treatment28.
Poor adherence was also found to ex-
plain up to 36% of the effect of cannabis
on the number of relapses29. Individuals
with suboptimal adherence were found to
have greater body mass index and were
less likely to live in independent housing
than individuals with continuous adher-
ence over 18 months. The magnitude of
these risk factors was small to moderate,
with a 2% greater likelihood of being
non-adherent for each point of increase
in body mass index, and a 25% greater
likelihood of being adherent in individu-
als living independently. In this study,
no other undesired outcomes were asso-
ciated with adherence status30.
Long-acting injectable (LAI) formula-
tions have also provided meaningful data.
When LAIs and oral formulations were
compared in RCTs, no overall difference
was found regarding relapse prevention
in the mid term after stabilization31. This
is not surprising, given that the control
groups taking oral medication in these
RCTs tend to include patients with better
treatment adherence and lower illness se-
verity. Non-adherence levels did not dif-
fer across ten meta-analyzed trials with
adherence data (p50.27)31.
When the same question was address-
ed by meta-analyzing mirror-image stud-
ies, where each research participant acts
as his/her own control, LAI treatment
phases, compared to those with oral an-
tipsychotics, were associated with a sig-
nificantly 57% lower risk of a next hos-
pitalization and a 62% reduced risk of
number of hospitalizations32. This is not
simply the result of the order of the oral
and LAI phases, as two trials confirmed
that the reverse switch (i.e. from an LAI
to an oral antipsychotic) was associ-
ated with poorer outcomes for the oral
phase33,34.
The finding of greater effectiveness of
LAIs in mirror image studies was repli-
cated in a meta-analysis of cohort stud-
ies, where the number of hospitalizations
was reduced by 15% (14 studies; 60,260
person-years), despite greater illness se-
verity in the LAI cohorts than the oral an-
tipsychotic treatment cohorts (p50.014)35.
Results were particularly apparent in
Scandinavian registries, that have fully
generalizable national samples. In a Finn-
ish national cohort, individuals treated
naturalistically with LAIs after their first
hospitalization for a schizophrenia epi-
sode had one third the risk of re-hospi-
talization than individuals on oral coun-
terparts of the same antipsychotics36.
This was replicated in a Swedish cohort
including all phases of illness, following
patients for a median of 6.9 years. Six of
the top eight antipsychotic monothera-
pies that were significantly superior re-
garding hospitalization risk compared to
not receiving any antipsychotic (hazard
ratios, HRs50.51-0.64) were LAIs (with
the two oral antipsychotics being cloza-
pine and olanzapine)37.
In a meta-analysis that compared ad-
verse effects with LAIs vs. the same oral
antipsychotics across sixteen RCTs with a
mean duration of one year, those prepara-
tions did not differ regarding 115 (96.6%)
of the 119 reported adverse effects38.
LAIs were more likely to present with
akinesia, low-density lipoprotein cho-
lesterol change and anxiety, whereas
oral antipsychotics were associated with
greater hyperprolactinemia. Furthermore,
there were no differences regarding treat-
ment discontinuation due to side effects
and mortality38. Little is known, how-
ever, about differences in adverse events
beyond one year of treatment.
Overall, assuming that the main advan-
tage of LAI over oral antipsychotics is
lower risk of non-adherence, this litera-
ture supports the relationship between
suboptimal adherence in the long term
and greater risk of relapse27,39, while dif-
ferences in adverse effects are small within
the time span of one year.
Placebo-controlled antipsychotic
maintenance treatment studies
Methodologically, placebo-controlled
maintenance RCTs have the advantage
of minimizing systematic differences be-
tween groups, yet their time frame is
only mid-term (i.e., 1-3 years following
stabilization), and their results assume
full long-term adherence with antipsycho-
tics (which is known to decrease over
time24). Increasing non-adherence even
in RCTs could lead to finding lower ef-
fect sizes in studies of longer duration.
A meta-analysis of 65 placebo-control-
led maintenance RCTs found an overall
NNT of 3 favoring antipsychotics over
placebo in preventing relapse, but overall
treatment effects tended to decrease as a
function of study duration9. The propor-
tion of individuals unimproved/worse
was lower on antipsychotics, but this
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difference decreased over time and was
non-significant in the longer-term studies.
Supporting the hypothesis that increas-
ing non-adherence on antipsychotics could
decrease antipsychotic maintenance ef-
ficacy, the authors found a significantly
greater relapse preventive effect (p50.03)
in studies comparing LAIs vs. placebo
(HR50.31) than oral medications vs. pla-
cebo (HR50.46). In LAI studies, non-ad-
herence could be identified and non-
adherent patients were discontinued or
excluded from the analyses9.
The number of patients with at least
one adverse effect did not differ between
antipsychotics and placebo, and did not
increase over time for individuals on
antipsychotics. No differences were ob-
served in sedation, although weight gain
and at least one movement disorder
were significantly more frequent during
antipsychotic treatment9.
Long-term cohort studies
Few placebo-controlled RCTs of anti-
psychotics last >3 years, with most last-
ing 1 year9. Most data beyond this
initial period are derived from non-ran-
domized, non-controlled cohort and reg-
ister studies. These have the advantage of
providing long-term data, not requiring
consent and being highly representative
of the overall population. However, given
the lack of randomization and controlled
intervention, subgroups are subject to var-
ious types of selection biases, and conclu-
sions are tentative.
Non-randomized cohort studies often
found that, at follow-up, individuals on
antipsychotics had equal or greater ill-
ness severity compared with those off
antipsychotics. For example, in the Suf-
folk county cohort, 175 individuals with
schizophrenia showed a clinical decline
over the 20-year follow-up period40. This
decline occurred despite high and con-
stant rates of antipsychotic prescription
(86.9% at baseline and 81.8% 20 years
later), and antipsychotic use was asso-
ciated with worse Global Assessment of
Functioning (GAF) scores and negative
symptoms, yet lower disorganization
and excitement40. In the Chicago cohort,
which followed 70 individuals with schizo-
phrenia from early illness for 20 years,
8% of the 15 unmedicated individuals
had some degree of psychotic symptoms,
versus 68% of the 25 individuals treated
continuously with antipsychotics14. In
the Northern Finland 1966 Birth Cohort,
which followed patients for almost 20
years, those who were off antipsychotics
were more often in remission, and no
differences in remission rates between
treatment groups were found41,42. Simi-
larly, the OPUS cohort in Denmark found
that, among the 90% of the individuals
who did not have sustained remission 10
years after their first episode, more were
on than off antipsychotics43,44.
Nevertheless, in those non-randomiz-
ed, uncontrolled studies, adherence lev-
els to antipsychotic treatment are un-
known, and most importantly, there is a
high risk of confounding by indication
and reverse causation, in that greater ill-
ness severity could be the cause of con-
tinued antipsychotic treatment, rather
than being the effect. Interestingly, dif-
ferent results were found in a retrospec-
tive cohort study of individuals with
schizophrenia whose access to antipsy-
chotic treatment had been restricted. In
this cohort from rural China, those who
had access to antipsychotics did substan-
tially better after 14 years than those
without access45.
Thus, despite the pattern of patients
with worse outcomes being overrepre-
sented in the treatment groups of several
cohort studies, the interpretation re-
garding cause and effect is difficult, and
reverse causation cannot be excluded.
On the other hand, results from large,
national samples analyzed with statistical
methods to adjust for baseline differences
support the notion that treatment failure
and hospitalization37, as well as mortality
risk from suicide46,47, are significantly
greater in patients not receiving antipsy-
chotics than in those who are.
Dose-reduction and dose-
discontinuation studies
Dose-reduction and dose-discontinua-
tion studies (DRDD) evaluate outcomes
associated with these treatment strategies
compared with long-term continuation of
antipsychotic treatment. DRDD studies
often have the advantage of a longer time
span than antipsychotic maintenance tri-
als, yet with greater degree of randomiza-
tion and control than naturalistic cohort
studies.
Wunderink et al13 conducted the study
with the longest follow-up period to date,
consisting of two phases. In the first
phase, 131 individuals with a first episode
of psychosis were allocated to 2 years of
either symptom guided DRDD or treat-
ment continuation48. The initial goal of
stopping antipsychotic treatment in the
DRDD group was changed to dose reduc-
tion only, due to too many relapses after
antipsychotic discontinuation. In the sec-
ond phase, 103 individuals were evalu-
ated once after 5 years of uncontrolled
community treatment13. In the initial
RCT, the DRDD group had twice as many
relapses as the maintenance group (43%
vs. 21%, p50.011), although about 20%
were able to successfully stop the med-
ication without relapses. There were no
differences in symptom severity, both
groups having low Positive and Negative
Syndrome Scale (PANSS) scores through-
out48. At 5 years, there were no differences
in relapse rates or symptom severity. How-
ever, recovery rates were twice as likely
in the initial dose-reduction group (40.4%
vs. 17.6%, p50.004), driven not by symp-
tomatic remission (69.2% vs. 66.7%, p5
0.79), but by functional remission (46.2%
vs. 19.6%, p50.01), and 8 of the 11 patients
off antipsychotics for 2 years were in the
original dose-reduction condition. These
results have been cited as important evi-
dence that antipsychotics could post-
pone rather than prevent relapse, while
impacting negatively on functional re-
covery in the long-term12,14,15,17,19.
These findings should be interpreted
with caution. As the authors acknowledge,
the participants had very low symptom
severity. Their conclusions might not
apply to more severely ill patients. Also,
the difference in antipsychotic exposure
between the two groups was only ques-
tionably clinically meaningful (1.4 mg/
day of haloperidol equivalents), without
significant differences in months per
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patient without antipsychotic prescrip-
tion. Less than 50% of the sample ap-
proached for the original RCT agreed to
participate, and only 43.7% of the pa-
tients at baseline were diagnosed with
schizophrenia48. Therefore, it remains pos-
sible that the results were related to fac-
tors other than the 2-year intervention
(i.e., DRDD or antipsychotic maintenance
dose continuation), which was followed
by 5 years of uncontrolled community
care, especially given the small dose dif-
ferences between treatment arms at 7
years. The lack of blinded assessment and
reverse causation could also have influ-
enced the results.
Antipsychotic dose reduction vs. stan-
dard maintenance dose has also been
examined in other studies with shorter
follow-up. In a meta-analysis of 13 trials
with follow-up of 24 and 104 weeks (11
trials lasting 1 year), Uchida et al49
found no differences between low anti-
psychotic dose (50-100% of the defined
daily doses50) and standard antipsychotic
dose, with respect to overall treatment
failure (p50.53) or hospitalization (p5
0.40). Yet, very low dose (<50% of the
defined daily doses50) were associated
with greater risk of hospitalization (p5
0.002) and relapse (p50.0004). In a pilot
study, cognitive symptoms were signifi-
cantly improved when the antipsychotic
dose was reduced to 50% of the defined
daily dose51.
A more recent uncontrolled discon-
tinuation study with an intermediate
follow-up period found greater rates of
symptom recurrence and lower func-
tional status in 46 individuals who had
recovered from a single psychotic epi-
sode and who had opted to being treated
with DRDD compared to 22 patients
who had opted for continuation of anti-
psychotic treatment for 3 years52.
Comments
There is a trade-off of strengths and
weaknesses between study designs, with
generally greater chance of bias in longer-
term studies and, especially, uncontrolled
studies in which more symptomatic and
impaired patients are more likely to re-
ceive long-term antipsychotic treatment.
There is consistent evidence, though, sup-
porting the efficacy of antipsychotics in
preventing relapse in the mid term (i.e.,
1-3 years) following stabilization. These
data come from studies of adherence,
trials of LAIs, national registries, placebo-
controlled maintenance trials and DRDD
trials.
Most, but not all, of the studies with
follow-up >3 years reported worse out-
comes associated with continued anti-
psychotic use. However, these results are
inconclusive, given small and selective
patient samples and extensive risk of
bias13-15. Conversely, long-term register
studies of much larger and representative
national cohorts of patients diagnosed
with schizophrenia confirmed significant-
ly less treatment failure and suicide-re-
lated mortality in antipsychotic-treated
patients compared to those not treated
with antipsychotics37,46,47.
In conclusion, there is a strong evi-
dence supporting mid-term efficacy, and
a lack of convincing evidence against
long-term efficacy of antipsychotic treat-
ment.
PHYSICAL MORBIDITY AND
MORTALITY
Schizophrenia is associated with a
well-established excess of physical mor-
bidity and premature mortality, while
antipsychotics are associated with car-
diovascular risk factors53-60.
Individuals with schizophrenia have a
greater prevalence of sedentary lifestyle,
obesity, cardiovascular illness, diabetes,
nicotine smoking and tobacco-related
disorders, sexually transmitted diseases,
obstetric complications, and altered
pain sensitivity61,62, while also having low-
er rates of health care services utilization
and medical treatment for such condi-
tions, which results in large unaddressed
gaps in medical care63. While it is unclear
the role that differences in health care sys-
tems play in physical morbidity in schizo-
phrenia, given the limited availability of
comparable data from a variety of coun-
tries61, it seems clear that this morbidity
plays an important role in reducing the
life expectancy of individuals with schizo-
phrenia across different settings.
A recent systematic review and meta-
analysis including 11 studies from vari-
ous countries found a weighted mean
decrement in life expectancy of 14.5 years
in patients with schizophrenia, with sig-
nificant variations depending on gender
and country64. While overall life expec-
tancy has recently increased in developed
countries, it is concerning that patients
with schizophrenia appear not to have
benefited from such improvements, so
that the mortality gap affecting these pa-
tients has increased65. The drivers of this
excess mortality seem to be poor physical
health and decreased health care service
utilization in patients with schizophre-
nia66,67.
In the US, natural causes account for
a vast majority of deaths, with only 1/7
related to unnatural causes (accidents,
suicide or homicide). Chronic medical
illness associated with smoking, obesity
and a sedentary lifestyle account for
most of the variance in premature mor-
tality. These results seem to vary across
countries, likely reflecting public health
characteristics. A 10-year longitudinal
study in Ethiopia found that premature
mortality was double in patients with
schizophrenia, with infectious diseases
accounting for almost half of the causes
of premature death, and with a greater
role of suicide in premature mortality68,69.
A similar pattern has been found in other
developing countries70,71.
The metabolic and cardiovascular side
effects of long-term antipsychotic treat-
ment have been a source of concern as
possible contributors to the increase of
physical morbidity and premature mor-
tality, especially in developed countries
where most of the mortality in schizo-
phrenia is related to consequences of
metabolic disturbance and cardiovascular
disease55,56,72. While the metabolic conse-
quences of long-term antipsychotic treat-
ment are widely appreciated53,54,57,58,60,
the understanding of their contribution
to morbidity and mortality in schizo-
phrenia has evolved over the last several
years.
There has been a growing literature
identifying health care service utilization
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patterns in schizophrenia associated with
worse outcomes. In a national Swedish
cohort, individuals with schizophrenia
were less likely to have received a diag-
nosis of cancer or ischemic heart disease
at the moment of dying of these causes73.
These data suggest poor prevention and
early treatment of medical conditions. In
another sample, individuals with schizo-
phrenia diagnosed with cardiovascular
illness were less likely to use lipid-low-
ering and anti-hypertensive medication,
which was altogether associated with
worse outcomes74. To what extent anti-
psychotic treatment moderates the asso-
ciation between schizophrenia and poor
health care utilization is not yet well un-
derstood.
The role of antipsychotics in reducing
premature mortality in schizophrenia
has been better characterized. Despite
antipsychotic treatment elevating car-
diovascular risk factors, long-term treat-
ment is consistently associated with low-
er mortality rates compared to no long-
term treatment46,47,75-77, but still higher
rates than in individuals without schizo-
phrenia46.
National registries constitute the best
approach to study the relationship be-
tween long-term antipsychotic treatment
and all-cause mortality as well as mortal-
ity related to cardiovascular illness, given
the availability of cumulative dose data.
In a seminal study, Tiihonen et al47 found
that, compared to individuals with schizo-
phrenia not receiving antipsychotic treat-
ment, those with longer antipsychotic
treatment had greater decrements in pre-
mature mortality, including from cardio-
vascular causes47. Given the possible sur-
vivor bias, the same group studied the
role of cumulative antipsychotic dose over
a 5-year period in influencing mortality
in schizophrenia adjusting for an exten-
sive number of variables. They found in
a separate sample that all – low, moder-
ate and high – antipsychotic cumulative
doses were associated with lower mortal-
ity rates than no antipsychotic use. Pa-
tients with schizophrenia with low and
moderate – but not high – cumulative
doses of antipsychotics had lower rates
of mortality due to cardiovascular disease,
whereas those with high – but not moder-
ate or low – doses had low mortality rates
due to suicide46.
Beyond these individual findings, a
recent meta-analysis found a consistent
association of antipsychotic use and dec-
rement in all-cause mortality, with some
evidence of a dose effect75. The seeming
disconnect between adverse antipsychot-
ic cardiovascular effects in short- and
longer-term studies and reduced (or, at
least, not elevated) all-cause and cardio-
vascular illness-related mortality in long-
term database studies may be explained
by a beneficial link between improved
psychiatric symptom control and im-
proved healthy lifestyle behaviors as well
as access to medical care78.
Despite being consistent, these register-
based findings should not be interpreted
as clearly establishing a causal relation-
ship between long-term antipsychotic
treatment and reduced all-cause mortal-
ity, given the limitations of observational
studies. However, national registries, de-
spite their exposure to potentially un-
measured confounders, currently consti-
tute the most adequate method to assess
the long-term effects of antipsychotics
on morbidity and mortality. Future re-
search should improve their design by
adjusting analyses for relevant potential
confounders that have not been mea-
sured (e.g., body mass index, metabolic
values, psychiatric illness symptom se-
verity, and functionality).
Comments
Individuals with schizophrenia have
significantly greater physical morbidity
and premature mortality than the gen-
eral population. While this finding is
related to unhealthier lifestyle and lower
health care service utilization, the role of
antipsychotics is less clear. Long-term
antipsychotic treatment is associated
with significantly greater rates of meta-
bolic and cardiovascular risk factors and
disease, yet patients treated with anti-
psychotics over the long-term seem to
have significantly lower mortality rates,
including death due to cardiovascular
disease, at low and moderate doses, com-
pared to individuals with schizophrenia
not receiving antipsychotics. This finding
has been replicated with large effect sizes
in various national registries, adjusting
for an extensive number of potential con-
founders, and with some evidence sug-
gesting a time and dose effect.
Though these data are limited by their
observational nature, they are consistent
enough to provide support for a favor-
able risk-benefit balance for the long-
term use of antipsychotics in schizo-
phrenia in reducing mortality.
BRAIN STRUCTURE AND
FUNCTIONING
Schizophrenia has been associated with
various brain volumetric abnormalities
since the emergence of neuroimaging79.
However, the nature and clinical relevance
of these findings still remain unclear80,
and even less so the role of antipsychot-
ics18. The cortical and subcortical regions
found to have lower volume in schizophre-
nia have most frequently been the ante-
rior cingulate cortex, insula, hippocam-
pus, and thalamus81,82, although several
other areas have been implicated, with
variability across studies probably due to
methodological differences.
Never treated patients with chronic
schizophrenia show a significantly ac-
celerated decline in prefrontal and tem-
poral cortical thickness83, suggesting a
neurodegenerative illness course. Re-
duced hippocampal and thalamic vol-
umes have been observed in individuals
at high risk of developing psychosis84.
High-risk individuals who transitioned
to psychosis presented with further pro-
gression of the whole brain volume re-
duction, even before antipsychotic treat-
ment85, and reductions in brain regions,
such as the anterior cingulate, have been
identified as potential biomarkers indica-
tive of greater risk of transition to psycho-
sis86. Despite grey matter reduction being
a consistent finding, what this means at
the neuropathological level is unclear87-91.
Brain tissue loss is a non-specific find-
ing, observed with antipsychotic expo-
sure92, changes in body weight93, alco-
hol use94,95, and steroid use96. Volumet-
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ric changes in drug-na€ıve patients do
not seem to be correlated with clinical
impairment or duration of illness, not
supporting a neurodegenerative hypoth-
esis83-86,97. A more recent perspective is
that volumetric reductions reflect a re-
duction of neuropil80, and that volumet-
ric variations can be heterogeneous in
schizophrenia, although decrements in
specific regions, such as the anterior cin-
gulate cortex, might be more homoge-
neous and therefore more specific to
that disorder98.
A generalized decrement of grey mat-
ter volume associated with antipsychotic
treatment duration and cumulative doses
has been repeatedly reported92,99. How-
ever, these studies are limited by the fact
that the duration and cumulative dose of
antipsychotics can be a marker of illness
severity or illness duration, making it
difficult to distinguish a reduction due to
illness severity, illness duration or anti-
psychotic exposure. In a meta-analysis of
longitudinal studies, the grey matter dec-
rement was directly related to the cumu-
lative dose of first-generation antipsy-
chotics during the window of observa-
tion, whereas the opposite was true for
second-generation antipsychotics97. This
finding is difficult to interpret and, as ac-
knowledged by the authors, may in part
be due to confounders, such as weight
gain associated with second-generation
antipsychotics.
Other findings contradict the notion
that antipsychotics cause a decrement
in grey matter in schizophrenia. The
ENIGMA neuroimaging consortium found
that, among 2,028 patients, antipsychotic-
na€ıve individuals had greater volumetric
deficits in the hippocampus compared
with antipsychotic-treated ones100, where-
as thalamus and basal ganglia volume
deficits in untreated patients have been
found to be corrected with antipsychotic
treatment92,100. A longitudinal study com-
paring grey matter volumes before and
after initiation of antipsychotic treatment
in first-episode patients found that anti-
psychotics minimized these decrements,
particularly in the striatum101. Another
study of patients who were stabilized on
antipsychotic treatment and allocated to
either antipsychotic maintenance or anti-
psychotic withdrawal found that after one
year there were no differences in volumetric
parameters between the two groups102.
Brain volume reductions need to be
interpreted within the context of the ef-
fects of untreated psychosis and of clini-
cal outcome findings. The reanalysis of a
study that had raised considerable con-
cern about the potential dose-dependent
adverse effect of antipsychotic treatment
on brain tissue loss103 revealed that the
duration of psychosis had a 3-fold greater
detrimental effect on total brain and fron-
tal lobe grey matter loss compared to the
duration of antipsychotic treatment104.
Furthermore, brain volumetric changes
do not seem to correlate with poor clin-
ical response or outcomes. In patients
treated with clozapine, both a grey mat-
ter decrement and a clinical improve-
ment have been reported105, whereas in
other studies the opposite was found106.
Moreover, measuring volumetric brain
changes during antipsychotic treatment
without assessing functional brain status
confuses the discussion. A cross-section-
al study in 23 antipsychotic-treated and
21 untreated first-episode patients found
significant cortical thinning within the
former group in the dorsolateral pre-
frontal and temporal cortex. However,
the medicated patient group showed sig-
nificantly higher dorsolateral prefrontal
cortex activation and significantly better
cognitive performance than the unmedi-
cated group107.
Thus, the evidence does not seem to
support a causal or detrimental relation-
ship between long-term antipsychotic
use and clinically relevant brain volu-
metric changes, with some data even
suggesting that brain volume reductions
could be associated with better brain
network integration.
Contrary to the ambiguous literature
on structural changes with chronic treat-
ment, findings on functional changes
have been more consistent. Long-term
antipsychotic treatment has been asso-
ciated with an increase in the number
and affinity of dopamine D2 receptors,
which results in a state of dopaminergic
supersensitivity, and has been replicated
in animal16,108 and human models109.
Tardive dyskinesia is a clinical conse-
quence of long-term antipsychotic use
that has been associated with dopami-
nergic supersensitivity110, but also other
possible mechanisms111, and with great-
er risk in genetically vulnerable popu-
lations112.
The estimated risk of tardive dyskine-
sia with first-generation antipsychotics
is 3-5% per year of exposure (at least
for the first 5 years)113, being lower
with second-generation antipsychotics114.
Early parkinsonism and higher antipsy-
chotic doses have been associated with
this side effect115. A recent meta-analysis
estimated a global mean prevalence of
25% in patients with schizophrenia treat-
ed with antipsychotics, with great vari-
ability depending on geographical and
treatment-related factors115.
Some studies reported that patients
with tardive dyskinesia are at greater risk
of rebound psychosis upon antipsychotic
withdrawal116, development of treatment
resistance117, and physical morbidity and
mortality118, although these results have
not been consistently replicated119. The
degree to which chronic antipsychotic ex-
posure plays a role in these potential out-
comes associated with tardive dyskinesia
(i.e., whether, beyond causing that side
effect, chronic antipsychotic treatment has
a causal role in these outcomes) is not well
understood120.
Second-generation antipsychotics should
be first-line maintenance treatment agents
to decrease the risk of tardive dyskinesia.
Two agents, valbenazine and deutetrabe-
nazine, have been recently approved in
the US for the treatment of this side effect
of antipsychotic treatment, having shown
moderate to high efficacy121,122.
Following the hypothesized mecha-
nism underlying tardive dyskinesia, do-
pamine supersensitivity related psycho-
sis either during antipsychotic treatment
or upon antipsychotic discontinuation
has been a theoretical concern117,123. The
hypothesis is that chronic dopaminergic
blockade resulting in dopamine D2 re-
ceptor upregulation and dopaminergic
hypersensitivity in the mesolimbic path-
way may increase the risk of relapse and
reduce antipsychotic efficacy in the long
term.
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Dopamine supersensitivity psychosis
was first described in a series of ten case
reports of patients who had abrupt onset
of psychosis upon the discontinuation of
antipsychotic treatment124. The existence
of this phenomenon has been contro-
versial and only supported by small
studies125. Nevertheless, there has been
a recent resurgent interest in dopamine
supersensitivity as a potential cause of
the emergence of treatment resistance
123,124,126,127. However, a meta-analysis
of RCTs found no differences in relapse
rates between abrupt and gradual anti-
psychotic withdrawal or between differ-
ent antipsychotic doses prior to discon-
tinuation9. Moreover, if dopamine hy-
persensitivity were a major reason for
the lack of long-term efficacy, then the
partial D2 agonist aripiprazole, which
has not been associated with upregula-
tion of dopamine D2 receptors, at least
in adult animal models128, should be
associated with significantly lower re-
lapse rates than full dopamine D2 antag-
onists, but there are no data to support
this129,130.
Comments
Overall, tardive dyskinesia is the clear-
est adverse clinical consequence in brain
functioning of long-term antipsychotic
treatment, which may be related to dopa-
mine supersensitivity in a subgroup of
vulnerable individuals. This risk should
be evaluated when considering long-
term antipsychotic treatment, and pre-
ventive strategies utilized. In addition,
patients should be examined before initi-
ating treatment to determine the pres-
ence of preexisting abnormal involuntary
movements.
Other effects of long-term antipsy-
chotic treatment on brain structure and
function, particularly neuropathological
changes and the risk of dopamine super-
sensitivity psychosis, are insufficiently
substantiated. The current literature does
not provide consistent evidence to sup-
port irreversible functional and structural
brain changes as a consequence of long-
term antipsychotic treatment other than
tardive dyskinesia.
THE ROLE OF PSYCHOSOCIAL
STRATEGIES IN MODIFYING THE
RISK-BENEFIT RATIO OF
ANTIPSYCHOTICS
While symptom reduction and re-
sponse, as well as relapse prevention, are
relevant outcomes, functional recovery is
a preeminent goal of treatment in schizo-
phrenia39. Unfortunately, when using cri-
teria based on both clinical and social
domains, recovery rates in schizophrenia
have remained low, with a meta-analyti-
cally derived median of 13.5% across five
decades, without improvement over time
(although only two studies contributed
data to the last decade)131. While, in an
aforementioned meta-analysis9, antipsy-
chotic maintenance treatment was supe-
rior to placebo in preventing relapse with
an NNT5 3, employment rates did not
differ, pointing toward the need for psy-
chosocial interventions to achieve im-
proved functional outcomes.
A recent meta-analysis found a signif-
icant small to medium association be-
tween clinical outcomes and personal
recovery, but psychotic symptoms –
which are the main target of antipsy-
chotic medications – showed a smaller
correlation than affective symptoms with
personal recovery132. These data under-
score that antipsychotics alone are insuf-
ficient and that adjunctive multimodal
psychosocial treatments are needed to
help stabilized patients achieve personal
recovery goals133.
The Schizophrenia Patient Outcomes
Research Team (PORT)134 reviewed the
evidence supporting a wide variety of
psychosocial interventions for the long-
term treatment of schizophrenia. The
committee recommended eight psycho-
social interventions with various indica-
tions and for different populations. Of
these, cognitive behavioral therapy (CBT)
was specifically recommended, with evi-
dence supporting its efficacy in reducing
positive, negative and overall symptoms
in individuals treated with antipsychotic
drugs135. While one of the goals of CBT is
psychoeducation on antipsychotic drug
adherence, the efficacy of CBT in improv-
ing this outcome has been inconclu-
sive136.
Interestingly, the evidence supporting
the efficacy of CBT in reducing psychotic
symptoms in individuals not taking anti-
psychotic medication137, or individuals
whose symptoms fail to respond to anti-
psychotic treatment138,139, has been more
consistent. This finding suggests that
the impact of CBT goes beyond improv-
ing adherence with antipsychotic medi-
cations, having an antipsychotic effect
on its own. However, to our knowledge,
there have not been head-to-head com-
parisons of CBT with long-term anti-
psychotic dose reduction strategies that
would provide data about CBT as a partial
or total substitution for long-term anti-
psychotic treatment139.
Family-based psychosocial treatments
were another of the interventions recom-
mended by the Schizophrenia PORT, with
evidence for reducing relapses and rehos-
pitalizations, and improving treatment
adherence134. These interventions are
based on psychoeducation, and are not
generally conceived as partial or total al-
ternatives to antipsychotics, but rather as
augmentation. In a large Chinese study
that randomized first-episode patients to
antipsychotic treatment alone or aug-
mented with family interventions for one
year, those in the augmentation arm were
less likely to discontinue antipsychotics,
showed greater improvements in insight,
social functioning and activities of daily
living, as well as access to employment
or education140. These results have been
substantially replicated141. In a trial that
compared family interventions augment-
ing regular or reduced antipsychotic dose,
those treated with low-dose antipsychot-
ics and family therapy were more likely to
relapse than those with family therapy
and regular antipsychotic dose142.
More recently, the Recovery After an
Initial Schizophrenia Episode - Early Treat-
ment Program (RAISE-ETP) study tested
the feasibility and effectiveness of the
integration of various psychosocial and
pharmacological interventions in the treat-
ment of 404 first psychotic episode pa-
tients in 34 community clinics across the
US133. This study compared coordinated
specialty care (which included CBT-based
psychotherapy, family education and sup-
port, supported education and/or employ-
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ment, and guided pharmacotherapy) with
treatment as usual, showing superiority
of the former in improving quality of life,
increasing time in education or at work,
and reducing symptom severity133. Be-
cause pharmacotherapy also differed be-
tween the two compared conditions, it is
difficult to draw firm conclusions regard-
ing effects of specific modalities. How-
ever, it seems unlikely that the psycho-
social interventions included in coordi-
nated specialty care could serve as sub-
stitute to medications, rather than as an
effective augmentation strategy, given the
lack of differences in the antipsychotic
dose used between the two arms143.
While psychosocial interventions seem
effective augmenting strategies, rather
than partial or total alternatives to anti-
psychotics, they can help improve the
long-term risk-benefit ratio of antipsy-
chotics by improving symptomatic and
psychosocial outcomes and by reducing
the risk of cardiometabolic side effects.
A meta-analysis of various non-phar-
macological interventions, ranging from
healthy lifestyle and behavioral inter-
ventions to CBT-based psychotherapies,
demonstrated their effectiveness in sig-
nificantly reducing body weight, body
mass index and serum lipids associated
with antipsychotic use144. Some of these
advantages persisted over time. Unfortu-
nately, challenges in engagement limit the
effectiveness of these interventions145,146.
Comments
Psychosocial interventions are effec-
tive augmentation strategies for the
treatment of schizophrenia, particularly
CBT-based interventions, which seem to
have antipsychotic effects independent
of improving antipsychotic adherence.
These interventions can be effectively
implemented beyond academic centers.
Evidence suggests that psychosocial
interventions can improve the long-term
risk-benefit ratio of antipsychotics by
improving functional, recovery-focused
outcomes and by decreasing the burden
associated with antipsychotic treatment,
rather than by necessarily allowing a
decrease in antipsychotic doses.
INDIVIDUAL DIFFERENCES IN THE
RISK-BENEFIT RATIO OF LONG-
TERM ANTIPSYCHOTIC
TREATMENT
While the diagnosis of schizophrenia
has been associated with poor outcome
and need for long-term antipsychotic
treatment, the heterogeneity in response
and illness course has resulted in calls to
broaden the view towards a psychosis
syndrome with variable outcome pat-
terns147,148. Some studies suggest that a
minority of patients could potentially dis-
continue antipsychotic treatment without
risk of relapse. The literature indicates
that this would apply to between 4% and
30% of the patients that are stabilized
after an acute episode43,48,52,149,150.
This variable range likely reflects het-
erogeneity in the studied populations,
criteria for diagnosis and relapse, dura-
tion of follow-up, and exposure to non-
pharmacologic interventions. Therefore,
we need better epidemiological data and
predictors of successful antipsychotic
discontinuation in patients presenting
with a psychotic syndrome consistent
with a diagnosis of schizophrenia. Some
studies have identified abrupt onset and
older age, female gender, higher GAF
scores, working, having a partner, living
independently and the absence of sub-
stance abuse as significant predictors
of better outcomes43,149, whereas others
have not been able to find any signifi-
cant predictors52.
A more consistent observation, how-
ever, is that previous successful anti-
psychotic withdrawal predicts successful
withdrawal during follow-up13,43,48,149.
This finding indicates that a minority of
individuals with a psychotic syndrome
fulfilling criteria for schizophrenia can
successfully discontinue antipsychotic
treatment, and the risk of relapse proba-
bly decreases as they move past a critical
high-risk period for relapse. However, to
date, there is no reliable evidence-based
method to identify such individuals.
This question, however, may benefit
from research that is being conducted
aimed at patient-level prediction of treat-
ment response. A wide range of predic-
tors have been recently identified, involv-
ing genetic151 and neuroimaging152-154
perspectives. Also, individual risk scores
based on clinical variables have been
developed to predict transition from clin-
ical high risk for psychosis to supra-
threshold psychosis155, and future re-
search could develop similar models to
predict treatment response. At present,
despite some promising findings, the field
is not ready to apply patient-level predic-
tors of antipsychotic response in real-
world care156. Future research should
equally address the development of pre-
diction models for successful treatment
discontinuation.
Comments
To date there is no evidence-based
strategy that enables us to identify indivi-
duals who would benefit from antipsy-
chotic dose reduction or discontinuation
with minimal increase in relapse risk. Fu-
ture research should capitalize on the re-
cent advances in patient-level predictors
of treatment response in order to identify
these low-risk individuals.
CONCLUSIONS AND
RECOMMENDATIONS
Overall, antipsychotic maintenance
treatment should be recommended for
the mid term (i.e., 1-3 years), since there
is strong evidence supporting efficacy of
antipsychotics in reducing relapses over
this time frame. Data on long-term out-
comes are more equivocal and, although
the effect of antipsychotics seems to
decrease over time, this could be an
artifact of long-term study designs. In-
creasing non-adherence and reverse
causation may play a significant role in
the observed time trends, while alter-
native hypotheses, including dopamine
supersensitivity psychosis, are less well
substantiated.
Additionally, mortality and neuropa-
thological findings do not support an
accrual of damage from cumulative anti-
psychotic dose and duration (with the
exception of tardive dyskinesia). On the
contrary, long-term antipsychotic main-
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tenance treatment has consistently been
associated with lower all-cause and
specific-cause mortality compared to
antipsychotic discontinuation in large
national and representative samples of
patients with schizophrenia.
Despite lack of long-term random-
ized, placebo-controlled trials and resid-
ual uncertainty regarding a subgroup of
patients who fulfill criteria for schizo-
phrenia and who may only suffer one
single psychotic episode, it is reasonable
to recommend antipsychotic treatment
in the long term (i.e., >3 years), although
with several additional suggestions. Con-
tinued antipsychotic treatment with
50% of the standard defined daily dose
should be implemented (going below
such doses increases the risk of relapse).
LAIs should be prioritized to minimize
breaks in treatment adherence, or to at
least make them known, allowing for
additional interventions to continue ade-
quate treatment. Second-generation anti-
psychotics should be preferred over first-
generation ones to minimize the risk of
tardive dyskinesia. Psychosocial inter-
ventions, particularly CBT and family-
based interventions, are useful as aug-
mentation, even when there are residual
or treatment resistant symptoms, yet
these therapies are not a substitute for
antipsychotic treatment. Some behav-
ioral interventions can also be used to
reduce some of the negative impacts of
continued antipsychotic treatment (i.e.,
metabolic side effects).
In patients who have achieved suc-
cessful antipsychotic discontinuation for
<1 year, close monitoring is recom-
mended, keeping in mind that only a
minority of patients can successfully dis-
continue antipsychotics. There are no
evidence-based methods to identify indi-
viduals who may be managed success-
fully with antipsychotic doses <50% of
standard antipsychotic doses, or who can
safely discontinue antipsychotics. There-
fore, the recommendation to continue
long-term treatment applies to patients
in general. While it is recognized that
shared decision making is relevant, clini-
cians should use the available evidence
and discuss the risks of the illness and
relapse-related biopsychosocial cost ver-
sus the risks of antipsychotic treatment,
and clearly present the probability of re-
lapse when stopping or continuing anti-
psychotic treatment. While the uncer-
tainty is largest after the first episode of
psychosis, following a second episode
the arguments for antipsychotic mainte-
nance treatment are even greater.
Future research should include pre-
dictive models of successful treatment
discontinuation in addition to predic-
tion of treatment response.
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